Schizoaffective disorder is a chronic mental health condition characterized by symptoms of both schizophrenia and mood ...

Classic psychedelics such as psilocybin and LSD enter the brain via the same receptors as serotonin, the body’s “feel good” ...

The Boston-based startup is developing what executives hope will be more effective treatments for depression, anxiety, and ...

Prescription digital therapeutics for mental health have the potential to increase patient access to care, but major barriers ...

MAC Clinical Research – one of Europe's largest independent clinical development firms - has been selected by ...

SINGAPORE: A teenager who received 16 years' jail for killing his schoolmate with an axe at River Valley High School lost his ...

FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central ...

The U.S. still lacks clinical guidelines for diagnosing and treating adult ADHD, leaving many adults undiagnosed and untreated. Experts are now working to address this gap.

SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline ...

The Company is currently developing CYB003, a proprietary deuterated psilocin program, about to enter Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004 ... as “may”, ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel ...